Ex­perts fret over a new hir­ing freeze at the FDA. Will the fall­out be tox­ic to drug re­views?

With hun­dreds of open po­si­tions and a slate of new ini­tia­tives to ex­e­cute on at the FDA, Pres­i­dent Don­ald Trump picked a par­tic­u­lar­ly in­con­ve­nient time to de­clare a hir­ing freeze for the fed­er­al gov­ern­ment.

No one re­al­ly knows how this is go­ing to play out, but the spec­u­la­tion is ram­pant that the FDA will be forced to cut loose from its re­view time­lines, which could have a big im­pact on a wide range of bio­phar­ma com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER